References:

1. Ringe JD. Meunier PJ.What is the future for fluoride in the treatment of? Osteoporosis Int. 1995;5:71-4.

2. Ringe JD. Stimulators of bone formation for the treatment Of? Osteoporosis. Int.: Meunier PJ, editor. Osteoporosis: diagnosis and management. London: Martin Dunitz, 199:131-48.

3. Kleerekoper M. Fluoride and the skeleton. Crit Rev LabSci1996;33:139-61.

4. Riggs BL.O'Fallon WM, Lane, A. Hodgson SF, Wahner HW.Muhs J. Chao E, Melton U. Clinical trial of fluoride therapy in Postmenopausal Osteoporotic, women: extended observations and additional analysis. J Bone Miner Res 1994;9:265-75.

5. Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson PD, Poindexter JR. Treatment of postmenopausal Osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial.Ann Intem Med 1995;123:401-8.

6. Farrerons J, Rodrigues de la Serna A, Buanabens N, Armadans L, Lopez-Navidad A, Yoldi B. Renau A. Vaque J. Sodium fluoride treatment is a major protector against vertebral and non-vertebral fractures when compared with other common treatments of osteoporosis: a longitudinal observational study. Calcif Tissue Int 1997,60:250-4.

7. Peichl P, Zamani 0, Kumpan W. Schmidt M, Rintelen B, Wilfert H, Brolll H. Antiosteoporotic therapy with monofluorophospate and calcium increases cortical and trabeculat vertebral bone density. Osteologie 1995;4:87-98.

8. Ringe JD, Kipshoven C, Rovati L, Setnikar I. Therapy ofidiopathic male osteoporosis: a 3-year study with calcium and low dose intermittent monofluorophosphate. In: Papapoulos SE, Lips P, Pols HAP, Johnston CC, Delmas PD, editors. Osteoporosis 1996. Amsterdam: Elsevier, 1996:383-90.

9. Mazess RB. Fracture risk: a role for compact bone. Calcif Tissue Int 1990;47:191-3.

10. Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS. Wahner HW, Muhs JM, Cedel SL. Melton LJ III. Effect of fluoride treatment onthe fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; "322:802-9.

11. Kleerekoper M, Peterson EL, Nelson DA, Philips E, Schork MA. Tilley BC, Parfitt AM. A randomized trial of sodium fluoride as treatment for postmenopausal osteoporosis. Osteoporos int 1991; 1:155-6 1.

12. Reginster JY, Meurmans L, Zegels B, Rovati LC, Giacovelli G. Taquet AN. Setnikir I, Collette J. Sodium monofluorophosphate reduces vertebral fractures in moderate postmenopausal osteoporosis. J Bone Miner Res 1997.12(Suppl 1):S 1 04.

13. Ringe JD, Dorst A. Kipshoven C, Rovati LC. Setnikar I. Avoidance of vertebral fractures in men with idiopathicosteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate. Osteoporos lnt 1998;8:47-52.

14. Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter T, Loeb G, Rouillon A, Barry S, Evreux JC, Avouac B, Merchandise X, and the FAVOStudy group. Fluoride salts are not better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos lnt 1998;8:4-12..

15. Alexandersen P, Hassager C, Sandholt I, Riis B. Christiansen C. Synergistic effect of hormone replacement therapy (HRT) combined with monofluorophosphate (MFP) on bone mass in late postmenopausal women. J Bone Miner Res 1997,12(Suppl 1):S104.

16. Schnitzier CM, Wing JR, Raal FJ, van der Mewe MT, Mesquita JM, Gear KA, Robson HI, Shires R. Fewer bone histomorphometric abnormalities with intermittent than with continuous slow-release sodium fluoride therapy),. Osteoporosis International 1997;7:376-89.

Received for publication 3 November 1997

Accepted in revised form 4 June 1999

Read the other Articles on Monofluorophosphate Plus Calcium